Plurilock Security (PLUR.V) seals $900k deal to Canadian Federal Government Agency
Top 5 Gainers and Losers: THRM.V, AGC.CN, FWZ.V
Zefiro Methane (ZEFI.E) has three ways to get paid taking over orphaned oil wells
Top 5 Gainers and Losers: RPX.V, HIGH.V, TML.TO
BC Bud (BCBC.C) applauds DEA action, provides corporate update
Top 5 Gainers and Losers: WEED.TO, TLRY.TO, ACB.TO
Today, Jody sits down once again with Ben Lightburn, CEO, director and co-founder of Filament Health (FH.NEO). Ben catches us up on the progress the medical psychedelics company has made since the start of the year including FDA approval of a Phase II clinical trial to investigate the effects of Filament’s lead drug candidate in treating patients suffering from major depressive disorder.
Enjoy!
Filament Health (FH.NEO) – Investor Roundtable Video #7